Results 61 to 70 of about 918,002 (207)
Outcomes of Redo Transcatheter Aortic Valve Replacement According to the Initial and Subsequent Valve Type [PDF]
As transcatheter aortic valve (TAV) replacement is increasingly used in patients with longer life expectancy, a sizable proportion will require redo TAV replacement (TAVR). The unique configuration of balloon-expandable TAV (bTAV) vs a self-expanding TAV
Marco Russo +236 more
core +1 more source
Management of Failed Bioprosthetic Aortic Valves: Mitigating Complications and Optimizing Outcomes
The use of bioprosthetic prostheses during surgical aortic valve replacements has increased dramatically over the last two decades, accounting for over 85% of surgical implantations.
Elizabeth L. Norton +3 more
doaj +1 more source
Gutter Rotation Technique for Percutaneous Ipsilateral Retrieval of a Ruptured SAPIEN‐3 Balloon
ABSTRACT Balloon rupture during transcatheter aortic valve replacement (TAVR) with balloon‐expandable valves is a rare but potentially serious complication that may result in incomplete valve expansion, difficult device retrieval, and vascular injury.
Anne Venkata Ganeshkumar +5 more
wiley +1 more source
Small aortic annulus poses a major challenge in aortic valve replacement due to the increased risk of prosthesis–patient mismatch (PPM) and increased surgical risk.
Shahzil Abdur Rehman Malik +6 more
doaj +1 more source
Transcatheter Aortic Valve Replacement
Transcatheter aortic valve replacement(TAVR) is a catheter‐based aortic valve replacement. It is primarily used to treat severe degenerative aortic valve stenosis. The first TAVR was performed in humans in 2002.
Alfonso, Carlos E +3 more
core +1 more source
Early Experience With Evoque Transcatheter Tricuspid Valve Replacement in Carcinoid Heart Disease
ABSTRACT Tricuspid regurgitation (TR) is nearly universal in carcinoid heart disease (CHD), but surgical replacement carries significant risk, and CHD was excluded from the landmark TRISCEND II trial. We present seven patients with CHD undergoing Evoque transcatheter tricuspid valve replacement (TTVR) at two tertiary centers.
Jackson S. Burton +3 more
wiley +1 more source
Will Transcatheter Aortic Valve Replacement (TAVR) be the Primary Therapy for Aortic Stenosis?
Transcatheter aortic valve replacement (TAVR) is increasingly used for the treatment of high or very high surgical risk patients with severe aortic stenosis (AS) or failing surgical bioprosthesis (valve-in-valve, VIV-TAVR). In TAVR, the collapsed transcatheter heart valve (THV) is introduced using the delivery system inserted from the femoral artery ...
Jose F. Condado, Peter C. Block
openaire +2 more sources
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya +9 more
wiley +1 more source
Interventional therapies for chronic heart failure: An overview of recent developments
Abstract Heart failure (HF), the final manifestation of most cardiovascular diseases, has become a major global health concern, affecting millions of individuals. Despite basic drug treatments, patients present with high morbidity and mortality rates. However, recent advancements in interventional therapy have shown promising results in improving the ...
Bingchen Guo +7 more
wiley +1 more source
Transcatheter Aortic Valve Implantation Current Indications and Future Directions
Degenerative heart valve disease is associated with significant morbidity and mortality and healthcare expenditures. Transcatheter heart valve repair and replacement has introduced a fundamental change in the therapeutic management and transcatheter ...
Mirjam Gauri Winkel +2 more
doaj +1 more source

